Community-acquired pneumonia (CAP) - Pipeline Insight, 2024

This “Community-acquired pneumonia (CAP) - Pipeline Insight, 2024” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Community-acquired pneumonia (CAP) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Community-acquired pneumonia (CAP): Understanding

Community-acquired pneumonia (CAP): Overview

Community-acquired pneumonia (CAP) is a leading cause of morbidity and mortality worldwide. The clinical presentation of CAP varies, ranging from mild pneumonia characterized by fever and productive cough to severe pneumonia characterized by respiratory distress and sepsis. Because of the wide spectrum of associated clinical features, CAP is a part of the differential diagnosis of nearly all respiratory illnesses. Community-acquired pneumonia (CAP) refers to an acute infection of the pulmonary parenchyma acquired outside of the hospital. CAP is one of the most common and morbid conditions encountered in clinical practice. In the United States, CAP accounts for over 4.5 million outpatient and emergency room visits annually, corresponding to approximately 0.4 percent of all encounters. CAP is the second most common cause of hospitalization and the most common infectious cause of death. The risk of CAP rises with age .The annual incidence of hospitalization for CAP among adults =65 years old is approximately 2000 per 100,000 in the United States. The figure is approximately three times higher than the general population and indicates that 2 percent of the older adult population will be hospitalized for CAP annually. Streptococcus pneumoniae (pneumococcus) and respiratory viruses are the most frequently detected pathogens in patients with CAP. CAP has been viewed as an infection of the lung parenchyma, primarily caused by bacterial or viral respiratory pathogens. The inflammatory response to infection is primarily responsible for the various clinical findings in CAP. Depending on the host and to some extent the pathogen, the disease can vary in its presentation from reasonably benign to fulminant and from mild to fatal in severity. The various signs and symptoms encountered involve not only the lung, but may be constitutional as well. As with any medical illness, the diagnosis is usually based on information obtained by a careful history, a physical examination and appropriate laboratory tests or procedures. In the case of CAP, a similar approach is used, modified as necessary based on severity of the initial presentation of the patient. The diagnosis of CAP is based upon findings suggestive of infection such as fever, chills or increased white count plus signs and/or symptoms localized to the respiratory system. These include cough, shortness of breath, increased sputum production, abnormal physical examination and a new or changed infiltrate on chest radiograph.

Community-acquired pneumonia (CAP) - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Community-acquired pneumonia (CAP) pipeline landscape is provided which includes the disease overview and Community-acquired pneumonia (CAP) treatment guidelines. The assessment part of the report embraces, in depth Community-acquired pneumonia (CAP) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Community-acquired pneumonia (CAP) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Community-acquired pneumonia (CAP) R&D. The therapies under development are focused on novel approaches to treat/improve Community-acquired pneumonia (CAP).

Community-acquired pneumonia (CAP) Emerging Drugs Chapters

This segment of the Community-acquired pneumonia (CAP) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Community-acquired pneumonia (CAP) Emerging Drugs

Gelsolin: BioAegis TherapeuticsPlasma gelsolin (pGSN) is an ancient, highly conserved human protein that is a highly abundant plasma protein in healthy individuals. Its role is to keep inflammation localized to the site of injury and to boost the body’s ability to clear pathogens. It regulates the pathogen clearance by enhancing NOS3 and scavenger receptor activity in macrophages and thereby improves antimicrobial defense in multiple gram positive and negative resistant and sensitive bacterial strains, as well as pneumonia secondary to influenza. Plasma gelsolin’s efficacy is not limited to bacterial infection. It addresses the inflammatory component of infection, including severe flu, as well as multiple inflammatory, autoimmune and degenerative diseases. Currently, the drug is in Phase I/II, stage of Clinical trial evaluation for the treatment of Community-acquired Pneumonia.

CAL 02: Combioxin SACAL02, is a unique therapeutic approach. It consists in using liposomes engineered to neutralize virulence effectors playing a critical role in the development of organ failure and fatal complications in severe infections. CAL02 is a phase 2-stage drug that has successfully been tested in ICU patients with severe community-acquired pneumonia.

Research programme: bacterial infection therapeutics: VaxdynVaxdyn, are committed to developing a vaccines pipeline against the most worrisome bacteria because their capacity of resistance to all or almost available antibiotics. The company is currently conducting research,to raise active immunity against 100% of circulating strains of each Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae in the population in hospitals or the community at risk of developing infections by these bacteria.

Trimodulin: BiotestTrimodulin, is a human plasma derived native polyvalent antibody preparation for intravenous administration. Currently, the drug is in Phase II stage of clinical trial evaluation for the treatment of community acquired pneumonia.

Community-acquired pneumonia (CAP): Therapeutic Assessment

This segment of the report provides insights about the different Community-acquired pneumonia (CAP) drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Community-acquired pneumonia (CAP)

There are approx. 8+ key companies which are developing the therapies for Community-acquired pneumonia (CAP). The companies which have their Community-acquired pneumonia (CAP) drug candidates in the most advanced stage, i.e. phase I /II include, BioAegis Therapeutics.

Phases

This report covers around 8+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Community-acquired pneumonia (CAP) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Community-acquired pneumonia (CAP): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Community-acquired pneumonia (CAP) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Community-acquired pneumonia (CAP) drugs.

Community-acquired pneumonia (CAP) Report Insights

• Community-acquired pneumonia (CAP) Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Community-acquired pneumonia (CAP) Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Community-acquired pneumonia (CAP) drugs?
• How many Community-acquired pneumonia (CAP) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Community-acquired pneumonia (CAP)?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Community-acquired pneumonia (CAP) therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Community-acquired pneumonia (CAP) and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• BioAegis Therapeutics
• Combioxin SA
• Vaxdyn
• Kyorin Pharmaceutical
• Biotest AG

Key Products

• Gelsolin
• CAL 02

Research programme: bacterial infection therapeutics- Lascufloxacin

• Trimodulin

This product will be delivered within 2 business days.